Hulikova, Alzbeta
Park, Kyung Chan
Loonat, Aminah A.
Gunadasa-Rohling, Mala
Curtis, M. Kate
Chung, Yu Jin
Wilson, Abigail
Carr, Carolyn A.
Trafford, Andrew W.
Fournier, Marjorie
Moshnikova, Anna
Andreev, Oleg A.
Reshetnyak, Yana K.
Riley, Paul R.
Smart, Nicola
Milne, Thomas A.
Crump, Nicholas T.
Swietach, Pawel http://orcid.org/0000-0002-9945-9473
Funding for this research was provided by:
British Heart Foundation (PG/16/66/32288)
Medical Research Council (MC_UU_12009/6, MC_UU_00016/6)
British Heart Foundation (RG/15/9/31534)
Article History
Received: 13 September 2021
Revised: 4 March 2022
Accepted: 11 March 2022
First Online: 31 March 2022
Declarations
:
: OAA and YKR are founders of pHLIP, Inc. They have shares in the company, but the company did not fund any part of the work. TAM and NTC are shareholders in and consultants for Dark Blue Therapeutics Ltd.